help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sassolas, G.
Right arrow Articles by Cabrera, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sassolas, G.
Right arrow Articles by Cabrera, P.

Journal of Clinical Endocrinology & Metabolism, Vol 68, 239-246, Copyright © 1989 by Endocrine Society


ARTICLES

Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men

G Sassolas, Y Khalfallah, JA Chayvialle, R Cohen, S Merabet, JP Casez, P Calvet and P Cabrera
Centre de Medecine Nucleaire, Lyon, France.

BIM 23014 (BIM) is a long-acting octapeptide somatostatin analog. We studied the effects of this analog on the secretion of GH, TSH, and gastroenteropancreatic hormones [secretin, motilin, and pancreatic polypeptide (PP)] in normal men. In the first protocol three BIM doses (125, 250, and 500 micrograms) and vehicle were administered sc in random order at 2000 h to eight normal young men. Plasma GH concentrations decreased during the first part of the night only after the highest dose (P less than 0.05). Plasma secretin levels did not change, while plasma motilin decreased after the 250- and 500- micrograms doses (P = 0.05 and P = 0.02, respectively), and plasma PP decreased after all three doses (P less than 0.05, P less than 0.01, and P less than 0.01, respectively) during the first part of the night. In the second protocol, eight men received BIM, administered by constant sc infusion during the night in a dose of 2 mg/12 h, or vehicle, either alone or in association with a 10 ng/kg.min iv GHRH or vehicle infusion. Nocturnal GH secretion was suppressed by the BIM infusion (P less than 0.001). GH secretion, stimulated by GHRH infusion (P less than 0.001), was reduced by concomitant BIM infusion (P less than 0.001) and was pulsatile during the combined infusions. BIM infusion suppressed the physiological nighttime rise in plasma TSH levels. Plasma motilin and PP levels were reduced by BIM, when administered either alone or in combination with GHRH. We conclude that: 1) BIM is capable of reducing GH secretion when administered sc in a dose of 500 micrograms and of abolishing nocturnal GH secretion when constantly infused at a dose of 2 mg/12 h; 2) BIM, constantly infused, reduces the nocturnal rise in TSH secretion; and 3) motilin and PP secretion are more sensitive than that of GH to BIM, as they are reduced by a lower dose.


This article has been cited by other articles:


Home page
J Clin PharmacolHome page
B. Astruc, P. Marbach, H. Bouterfa, C. Denot, M. Safari, A. Vitaliti, and M. Sheppard
Long-Acting Octreotide and Prolonged-Release Lanreotide Formulations Have Different Pharmacokinetic Profiles
J. Clin. Pharmacol., July 1, 2005; 45(7): 836 - 844.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
E. V. Dimaraki, C. A. Jaffe, R. Demott-Friberg, M. Russell-Aulet, C. Y. Bowers, P. Marbach, and A. L. Barkan
Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator
Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E489 - E495.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. M. Kuhn, S. Arlot, H. Lefebvre, P. Caron, C. Cortet-Rudelli, F. Archambaud, P. Chanson, A. Tabarin, M. Goth, J. Blumberg, et al.
Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide
J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1487 - 1491.
[Abstract] [Full Text]


Home page
CirculationHome page
M. K. Hong, K. M. Kent, R. Mehran, G. S. Mintz, F. O. Tio, M. Foegh, S. C. Wong, S. S. Cathapermal, and M. B. Leon
Continuous Subcutaneous Angiopeptin Treatment Significantly Reduces Neointimal Hyperplasia in a Porcine Coronary In-Stent Restenosis Model
Circulation, January 21, 1997; 95(2): 449 - 454.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Caron, I. Morange-Ramos, M. Cogne, and P. Jaquet
Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 18 - 22.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
H. G. Maheshwari, S. S. Pezzoli, A. Rahim, S. M. Shalet, M. O. Thorner, and G. Baumann
Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance
Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E943 - E951.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society